Influence of CYP2C9 Genotype on Clinical Efficacy of Tenoxicam

PHASE4CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

July 1, 2019

Study Completion Date

November 1, 2019

Conditions
Molar, ThirdPain
Interventions
DRUG

Tenoxicam

After extraction of at least one third molar, 89 patients will be treated with tenoxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed.

Trial Locations (1)

17012901

University of Sao Paulo, Bauru

All Listed Sponsors
lead

University of Sao Paulo

OTHER

NCT04182191 - Influence of CYP2C9 Genotype on Clinical Efficacy of Tenoxicam | Biotech Hunter | Biotech Hunter